A venture capital investor warns that Europe’s slate of regulatory reforms will do little to shift investment decisions ...

In an interview with the Pink Sheet, de Claro said he plans to continue refining programs on review efficiency and innovation, regulatory science, and external engagement, and said the speedy review ...

With positive Phase II data for its oral biologic cocktail in curing and preventing recurrence of CDI, Lumen hopes to find a deep-pocketed partner to help fund a larger Phase III study.

As the CLARITY trials hit primary and key secondary endpoints, execs from Roivant subsidiary Priovant dug into how the non-infectious uveitis (NIU) treatment landscape has evolved.

UK government confirms support for continued acceptance of CE-marked medical devices in Great Britain on a long-term basis.

Sovereign AI and trusted research environments are quietly reshaping how pharma companies access and analyze data.

Women’s sports organizations support their athletes’ health and fitness to extend their careers, but research is limited on ...

As China’s new cosmetics safety standard starts a compliance clock for brands, cosmetic chemist Kelly Dobos explains in an ...

At recent CRN conference, USANA chief scientific officer Kathryn Armstrong says the firm uses six-point check list to ...

Agilent’s $240m Proscia deal targets a digital pathology market split in two — clinical labs still largely on glass, biopharma already on screens — with companion diagnostics the clearest near-term ...

Intuitive Surgical grew Q3 revenue 22% to $3.05bn at a 42% non-GAAP operating margin, but a newly quantified cut to da Vinci instrument pricing, a $450m class action settlement and 10% US procedure ...

The big players have jockeyed into position through business development and are ramping up clinical trial programs with the goal of changing the standard of care in cancer.